KSF probes AtaiBeckley's $6.75-per-share sale to Eli Lilly

Kahn Swick & Foti has opened an investigation into whether Eli Lilly's proposed acquisition of AtaiBeckley fairly compensates shareholders.

Kahn Swick & Foti LLC is investigating whether the $6.75-per-share cash offer plus up to $2.50 in contingent value rights that Eli Lilly and Company proposed for AtaiBeckley Inc. adequately values the psychedelic therapeutics developer, the law firm said Monday.

"We are examining whether the consideration and the process that led to it are adequate, or whether the consideration undervalues the Company," said Lewis S. Kahn, managing partner at Kahn Swick & Foti.

Under the terms, AtaiBeckley shareholders would receive $6.75 per share in cash plus up to $2.50 per share through a Contingent Value Right tied to development and regulatory milestones for the BPL-003 and VLS-01 programs. The total deal value and premium to AtaiBeckley's undisturbed trading price have not yet been disclosed. AtaiBeckley trades on the Nasdaq Global Market under ticker ATAI, while Eli Lilly trades on the New York Stock Exchange under LLY.

The investigation adds legal uncertainty to a strategic acquisition in the mental health and psychedelic therapeutics space, where Eli Lilly has been expanding its neuroscience pipeline. If KSF or other shareholder plaintiffs determine the offer undervalues the company, the deal could face litigation, a revised bid, or extended regulatory review. Shareholders can contact KSF at no cost to discuss their legal rights regarding the proposed sale, the firm said.

CVR structure carries valuation risk

The contingent value right component means the actual per-share consideration could range from $6.75 to $9.25 depending on whether BPL-003 and VLS-01 hit their specified development and regulatory milestones. This structure is common in biopharmaceutical M&A, where acquirers use milestone-based payments to bridge gaps between buyer and seller valuations of early-stage assets. For AtaiBeckley shareholders, the CVR introduces uncertainty about the final value they receive, as milestone achievement is not guaranteed.

KSF, whose partners include former Louisiana Attorney General Charles C. Foti Jr., has been active in reviewing M&A transactions this year. The firm is simultaneously investigating the proposed sales of Arcosa Inc. to CRH at $150 per share and Crinetics Pharmaceuticals to Vertex Pharmaceuticals at $85 per share, according to separate announcements Monday. This pattern of concurrent investigations reflects heightened scrutiny of deal valuations across sectors, from industrial infrastructure to rare disease therapeutics.

What happens next

The investigation's outcome could shape whether the deal proceeds on current terms or faces challenges. Shareholder litigation in M&A transactions frequently results in supplemental disclosures, increased consideration, or in some cases, deal termination. The proposed transaction will also require customary regulatory approvals and a shareholder vote, though specific timelines have not been disclosed.

For Eli Lilly, the legal overhang adds another layer of review to a deal that expands its position in the mental health treatment market. For AtaiBeckley shareholders, the investigation represents an opportunity to scrutinize whether the board secured fair value in a sale process that has yet to be fully detailed. The CVR structure means the ultimate value delivered to shareholders depends on clinical and regulatory outcomes for BPL-003 and VLS-01, programs that carry inherent development risk.

This article is for informational purposes only and does not constitute investment advice.